Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer. Author(s): Brenna L. Brady, PhD, Matthew Lucci, MPH +7 More.

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

Ascites Associated With Intravenous Paclitaxel - Medscape - Oct 14, 2003. Tables. References. Authors and Disclosures. Authors and Disclosures Author(s) Virna Ignacio Almuete, RPh .

Paclitaxel, often sold under the brand name Taxol, is one of the most widely prescribed chemotherapy drugs and is used to treat a variety of cancers, including breast, ovarian, and lung.

Intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: A feasibility study.. JCO 29 , 5054-5054 (2011). DOI: ...

The combination use of oral paclitaxel and encequidar was not only associated with greater efficacy in patients with metastatic breast cancer, but also lower rates of chemotherapy-induced peripheral ...

The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on Oct. 8, 2024.

M Markman, BN Bundy, DS Alberts, etal : Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and ...

--Athenex, Inc.,, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Meštrović, Tomislav. (2023, July 01). Paclitaxel Side-Effects.